Maryanoff B E, Qiu X, Padmanabhan K P, Tulinsky A, Almond H R, Andrade-Gordon P, Greco M N, Kauffman J A, Nicolaou K C, Liu A
Drug Discovery Division, R. W. Johnson Pharmaceutical Research Institute, Spring House, PA 19477.
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8048-52. doi: 10.1073/pnas.90.17.8048.
The macrocyclic peptide cyclotheonamide A (CtA), isolated from the marine sponge Theonella sp., represents an unusual class of serine protease inhibitor. A complex of this inhibitor with human alpha-thrombin, a protease central to the bioregulation of thrombosis and hemostasis, was studied by x-ray crystallography. This work (2.3-A resolution) confirms the structure of CtA and reveals intimate details about its molecular recognition within the enzyme active site. Interactions due to the "Pro-Arg motif" (Arg occupancy of the S1 specificity pocket; formation of a hydrogen-bonded two-strand antiparallel beta-sheet with Ser214-Gly216) and the alpha-keto amide group of CtA are primarily responsible for binding to thrombin, with the alpha-keto amide serving as a transition-state analogue. A special interaction with the "insertion loop" of thrombin (Tyr60A-Thr60I) is manifested through engagement of the hydroxyphenyl group of CtA with Trp60D as part of an "aromatic stacking chain." Biochemical inhibition data (Ki values at 37 degrees C) were obtained for CtA with thrombin and a diverse collection of serine proteases. Thus, CtA is just a moderate inhibitor of human alpha-thrombin (Ki = 0.18 microM) but a potent inhibitor of trypsin (Ki = 0.023 microM) and streptokinase (Ki = 0.035 microM). The relative lack of potency of CtA as a thrombin inhibitor is discussed with respect to certain structural features of the enzyme complex. We also report the total synthesis of CtA, by a convergent [2 + 3] fragment-condensation approach, to serve the preparation of cyclotheonamide analogues for structure-function studies.
从海洋海绵Theonella sp.中分离出的大环肽环西奥酰胺A(CtA)代表了一类不同寻常的丝氨酸蛋白酶抑制剂。通过X射线晶体学研究了这种抑制剂与人类α-凝血酶(一种在血栓形成和止血的生物调节中起核心作用的蛋白酶)形成的复合物。这项工作(分辨率为2.3埃)确定了CtA的结构,并揭示了其在酶活性位点内分子识别的详细信息。由于“Pro-Arg基序”(S1特异性口袋中的精氨酸占据;与Ser214-Gly216形成氢键连接的双股反平行β-折叠)和CtA的α-酮酰胺基团之间的相互作用主要负责与凝血酶结合,其中α-酮酰胺充当过渡态类似物。与凝血酶的“插入环”(Tyr60A-Thr60I)的特殊相互作用通过CtA的羟基苯基与Trp60D的结合表现出来,这是“芳香堆积链”的一部分。获得了CtA对凝血酶和多种丝氨酸蛋白酶的生化抑制数据(37℃时的Ki值)。因此,CtA只是人类α-凝血酶的中度抑制剂(Ki = 0.18微摩尔),但却是胰蛋白酶(Ki = 0.023微摩尔)和链激酶(Ki = 0.035微摩尔)的强效抑制剂。针对酶复合物的某些结构特征,讨论了CtA作为凝血酶抑制剂相对缺乏效力的问题。我们还报告了通过收敛性[2 + 3]片段缩合方法全合成CtA,以用于制备用于结构-功能研究的环西奥酰胺类似物。